Protein toxins of the Shiga family have become potent tools in studying a number of intracellular transport events such as endocytosis, the communication between endosomes and the biosynthetic/secretory pathway, and retrograde transport from the Golgi apparatus to the endoplasmic reticulum. It seems clear today that most of these transport events can be explained from the toxins' interactions with cellular factors. This review will primarily focus on the discussion of recent data obtained on Shiga toxin and related toxins. We will point out to what extent the study of these proteins has opened new avenues for the development of intracellular targeting tools.
After delivery to endosomes, internalized toxins can follow distinct pathways. Some toxins, such as diphtheria toxin, are translocated in a pH-dependent manner from endosomes to the cytosol. This process is now relatively well understood (12) . The toxins of the Shiga family, however, are transported to the Golgi apparatus ( Figure 1) . We have recently shown that the B-subunit of Shiga toxin passes directly from early/ recycling endosomes to the Golgi apparatus, circumventing the late endocytic pathway (13) . Interestingly, the B-subunit appears to use a pathway taken by endogenous proteins, such as trans-Golgi network (TGN) protein TGN38, that cycle between plasma membrane and the TGN (13, 14) . In contrast, the mannose-6-phosphate receptor passes in a Rab9-dependent manner from late endosomes to the TGN (15) , and similar transport has recently been reported for the protease furin (16) (Figure 1 ). Work is in progress in our laboratory to unravel the molecular mechanisms underlying early endosomes-to-Golgi transport. It is likely that clathrin/ AP-1 coats are involved, as shown by the colocalization between g-adaptin and B-subunit on endosomal membranes (13) . Preliminary results indicate that Rab11, a small GTPase associated with the recycling endosome, may regulate this pathway. The pathway followed by ricin to reach the TGN is also under investigation. Internalized ricin can enter the Golgi apparatus in cells overexpressing a dominant-negative mutant of Rab9 (K. Sandvig, personal communication), a small GTPase regulating transport from late endosomes to the TGN (15) , suggesting that ricin may follow the same route as Shiga toxin. Using a cell line overexpressing mutant dynamin, Sandvig and colleagues have also presented biochemical data that suggest a role for dynamin in the regulation of endosomes-to-Golgi transport of ricin (17) . In contrast, when intoxication of cells by ricin was measured under similar experimental conditions, no effect was observed (18) . This discrepancy may be attributed to the different sensitivities of the assays.
From the TGN, the toxins of the Shiga family enter Golgi stacks and undergo retrograde transport to the endoplasmic reticulum (ER). Transport to the ER is thought to be necessary for transfer to the cytosol (see below). Some toxins, such as cholera toxin and Pseudomonas exotoxin, carry KDEL or KDEL-like motifs at their C-terminus, and appear to follow the KDEL receptor pathway. For instance, the delivery of these toxins to the ER is blocked upon microinjection of antibodies to the KDEL receptor and in the case of cholera toxin, upon microinjection of antibodies to native COPI coatomer (19, 20) , both of which are markers of the previously described retrograde transport pathway (21) . Shiga toxin does not have a KDEL motif, but still finds its way to the ER. The addition of an ectopic KDEL retrieval sequence to the C-terminus of the B-subunit does not greatly increase the efficiency of its retrograde transport, suggesting that the protein might follow a KDEL receptor-independent pathway (22) . In fact, it was recently shown that microinjection of anti-COPI and anti-KDEL-receptor antibodies does not affect Golgi-to-ER transport of Shiga toxin and certain Golgi enzymes (23; see also 24) . This pathway appears to involve the small GTPase Rab6 since a dominant-negative mutant of Rab6 blocks Shiga toxin B-subunit delivery to the ER. In contrast, no effect is observed on the recycling of another protein, ERGIC 53, which follows the COPI-dependent retrograde transport pathway. In another study, the Shiga toxin B-subunit was shown in live cells to be transported between Golgi and ER within Rab6 positive tubular membrane structures (25) . Again, these structures appear to be devoid of classical recycling markers, such as KDEL-receptor. These studies illustrate that, as in the case of endosomes-to-Golgi transport, toxins exploit pre-existing, yet basically unexplored transport routes to reach their final destinations. The molecular machinery that constitutes the COPI-independent retrograde transport pathway between the Golgi apparatus and the ER remains to be identified except for Rab6 and its effector molecules, such as Rabkinesin-6 (26) and GAPCenA (27) .
The knowledge of protein toxin intracellular transport routes allows their use to target components from the outside of the cell to selected intracellular sites. This principle has been exploited by Grinstein and colleagues who devised experiments to measure the pH of the Golgi apparatus and the ER on living cells using fluorophores coupled to the Shiga toxin B-subunit and mutant versions thereof (28, 29) . Protein toxins have also served to introduce antigenic peptides into the exogenous major histocompatability complex (MHC) class I restricted antigen presentation pathway (30 -33; for review, see 34) . Surprisingly, even the B-subunit of Shiga toxin alone can drive MHC class I restricted antigen presentation (35; see chapter 3 below). Shiga toxin B-subunit (represented as red doughnut shaped structures; B-subunit transport pathways in red arrows) is internalized into early/recycling endosomes and then transported directly to the Golgi apparatus, from where the protein gains access to the ER. The GTPase Rab11 and AP1/clathrin coats may regulate transport from early/recycling endosomes to the Golgi apparatus (see text). The mannose-6-phosphate receptor and furin pass from late endosomes to the Golgi apparatus (green arrow). The B-subunit transport route from the Golgi apparatus to the ER (red broken arrows) appears to be different from the well-known COPI-dependent retrograde transport route (blue arrow). Black arrows represent classical transport routes (anterograde transport in the biosynthetic/secretory pathway, endocytosis, endocytic transport, and recycling). Note that modified ricin and Shiga toxin B-subunit allow quantification of retrograde transport to the TGN (by sulfation) and to the ER (by glycosylation).
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The Physiology of Toxin-Lipid Interaction
Considerable progress has been made in the identification of cellular factors that regulate toxin traffic along recently discovered routes (see above). In contrast, still very little is known about the toxin-specific determinants of their intracellular traffic. In the case of Shiga toxin and the related verotoxins, the glycolipid Gb 3 appears to play a pivotal role. Gb 3 has been identified as the cellular Shiga toxin receptor (36) . Studies using butyric acid suggest the existence of a parallelism between toxin transport to early compartments of the biosynthetic/secretory pathway and the expression of certain Gb 3 isoforms (37-40). However, since butyric acid has a number of effects in addition to inducing changes in the cellular Gb 3 pattern, the precise mechanism for cell sensitization by the drug remains to be established.
Lingwood and colleagues have suggested that Gb 3 may actually function in the intracellular transport of host cell proteins, such as CD19 (41) . In fact, in Daudi Burkitt's lymphoma cell lines in which Gb 3 was not expressed or in which its expression was inhibited, CD19 intracellular routing was altered. It is tempting speculate that Shiga toxin and verotoxins have evolved to exploit a pre-existing lipid-guided transport machinery that, in the cellular context, assures the intracellular delivery of certain proteins. The toxins have recently been joined by human immunodeficiency virus (HIV), which uses Gb 3 as a co-receptor (42, 43) . Further studies will show whether HIV depends on Gb 3 merely to bind to target cells, or whether the intracellular transport characteristics of Gb 3 determine HIV entry.
Another important question, namely that of the individual functions of toxin subunits, has also been addressed. This question was raised when it became apparent that the (nontoxic) receptor-binding B-subunits have effects on target cells when added in the absence of the (toxic) A-subunits. In the case of Shiga toxin, the B-subunit was found to induce apoptosis in Burkitt's lymphoma derived B-lymphocytes (44) and in astrocytoma cells (45) , while in other cells only the holotoxin-induced apoptosis (46) . Interestingly, at least some of the signaling function required for the induction of these effects lies in the B-subunit's interaction with its cellular receptor, the glycolipid Gb 3 , since an anti-B-subunit antibody also induced apoptosis in Burkitt's lymphoma derived Blymphocytes (47) . In human glomerular mesangial cells, Shiga holotoxin inhibits protein biosynthesis, while the B-subunit alone inhibits cell proliferation in a protein biosynthesisindependent manner (48) . Other examples of the surprising variety of subunit specific toxin effects have been reported. In human monocytes and mouse macrophages, Shiga toxin does not induce an inhibition of protein biosynthesis, even at high concentrations (49) (50) (51) (52) . However, these cells secrete nitric oxide or certain cytokines, such as interleukin-2 and tumor necrosis factor a, after contact with the toxin.
How the B-subunit transduces its activity remains a mystery. One might suggest that Gb 3 -binding by B-subunits leads to clustering of the lipid and subsequent stimulation of signaltransduction events, as suggested for microdomain forming lipids (for review, see 53). Alternatively, the B-subunit could also bind directly to cellular proteins whose activity would thus be modulated. In any case, these data argue in favor of the idea that B-subunits are more than simple cell targeting devices.
The Ins and Outs of Protein Toxins -A Question of Subunits?
Membrane transfer of Shiga family members has been a matter of debate, obviously except for the finding that this process is pH-independent. Based on the fact that, for some of these toxins, transport to the ER has unequivocally been documented by morphological and biochemical means (22,54 -56) , it is commonly argued that transfer happens at the level of this compartment. Olsnes and colleagues have recently provided direct evidence for this hypothesis (56, 57) . First, it was shown that ricin carrying an N-glycosylation site is in fact recovered as a glycosylated protein from the cytosol of target cells, suggesting that it passes via the ER before arriving in the cytosol (56) . Second, the proteasome inhibitor lactacystein sensitizes target cells to ricin, and ricin A-chain can be co-immunoprecipitated with the translocon-constituent Sec61a presumably as it passes through the ER (57). These studies have been extended through the demonstration that ricin introduced into tobacco protoblasts can leave the endomembrane system, probably by retro-translocation at the level of the ER (58) . In further agreement, it was also found that an inactivated ricin mutant, after its co-translational introduction into the ER of yeast, passes in a Sec61-dependent fashion into the cytosol (M. Lord, personal communication). These data thus suggest that a major membrane translocation activity for ricin, and potentially other toxins of the Shiga family, localizes to the ER. It should be mentioned, however, that other studies indicate the existence of membrane transfer from early compartments of the endocytic pathway (59) , and at the moment it cannot be excluded that several different mechanisms exist which allow bacterial toxins of the Shiga family to escape from the lumen of the compartments at variable intracellular sites. These mechanisms may co-exist in the same cells or be specific for particular cell types.
In the context of membrane translocation, it is noteworthy that Shiga toxin B-subunit can drive MHC class I restricted antigen presentation in B-lymphocytes and cells derived from the monocyte lineage, namely dendritic cells (35) and macrophages (L. Johannes, E. Tartour, J. Salamero, and B.Goud, manuscript in preparation). It seems likely that the B-subunit introduces antigenic peptides into the exogenous class I presentation pathway since: i) presentation is insensitive to inhibitors of lysosomal degradation, but inhibited by brefeldin A (35) ; ii) in mouse dendritic cells, the proteasome inhibitor lactacystein inhibits antigen presentation; and iii) dendritic cells obtained from mice with genetically inactivated TAP transporter do not present B-subunit-coupled antigenic peptides (E. Tartour and L. Johannes manuscript in 121 Traffic 2000: 1: 119-123 preparation). It appears that in these antigen presenting cells the B-subunit bypass the biosynthetic/secretory pathway, but surprisingly, it can be detected on nucleoli (L. Johannes, E. Tartour, J. Salamero, and B.Goud, manuscript in preparation). This new pathway may be correlated to the absence of protein biosynthesis inhibition in these cells (see above), and is again consistent with the hypothesis that several membrane transfer mechanisms exist for toxins of the Shiga family.
Conclusion
Research in recent years has revealed that bacterial protein toxins of the Shiga family follow a number of inward-bound intracellular pathways that have often been overlooked before. They have thus enriched our picture of the communication between intracellular compartments. Furthermore, a similar diversity may exist for the mechanisms that allow these proteins to have access to their cytosolic target molecules. Finally, the knowledge of their intracellular transport and the possibility of modifying their sequence in defined ways has opened new avenues to their use as intracellular targeting devices.
